Investigational therapies for renal disease-induced anemia
Authors:
- 21 May 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 25 (8) , 901-916
Abstract
Introduction: The main pillars for the treatment of chronic kidney disease (CKD) associated anemia are peptidic erythropoiesis stimulating agents (ESAs) and iron preparations. Both approaches benefit from long-term efficacy and safety data but are surrounded by clinical and economic concerns, driving the search for novel anti-anemic drugs. Areas covered: By answering pivotal questions, the authors describe the recent developments of next generation ESAs, introduce cutting-edge iron formulations and focus on investigational approaches that interact with pathways involved in erythropoietin (Epo) synthesis and myeloid hematopoiesis. Finally, the challenges encountered with these drug candidates are discussed. Expert opinion: Current peptidic ESAs are effective and well-tolerated, but are costly, require parenteral application and iron supplementation. ESA resistance may develop calling for increased doses. Therefore, orally available hypoxia-inducible factor (HIF) stabilizing compounds are attractive alternatives, which may be approved in the near future. Prominent compounds are molidustat, daprodustat and roxadustat. HIF stabilizers suppress hepcidin production and improve iron balance as the present ESAs, but also raise safety concerns in association with their pleiotropic actions. Other investigational erythropoietic biologics are growth-differentiation factor-11 (GDF11) ligand traps (sotatercept, luspatercept), which are also well advanced in development. Possibly, they will provide an add-on for established therapies. However, immunogenicity of these compounds still needs to be carefully investigated.Keywords
This publication has 101 references indexed in Scilit:
- Hypoxia-Inducible Factors in Physiology and MedicineCell, 2012
- Targeting the hepcidin–ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammationAmerican Journal of Hematology, 2011
- Reduced SMAD7 Leads to Overactivation of TGF-β Signaling in MDS that Can Be Reversed by a Specific Inhibitor of TGF-β Receptor I KinaseCancer Research, 2011
- BMP6 Treatment Compensates for the Molecular Defect and Ameliorates Hemochromatosis in Hfe Knockout MiceGastroenterology, 2010
- Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic CardiomyopathyCirculation, 2010
- Reactivation of Hepatic EPO Synthesis in Mice After PHD LossScience, 2010
- BMP6 is a key endogenous regulator of hepcidin expression and iron metabolismNature Genetics, 2009
- BMP type I receptor inhibition reduces heterotopic ossificationNature Medicine, 2008
- The Serine Protease TMPRSS6 Is Required to Sense Iron DeficiencyScience, 2008
- Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balanceJournal of Clinical Investigation, 2007